Gastrointestinal adverse events of semaglutide in patients with overweight or obesity

Eur J Intern Med. 2022 Dec:106:138-139. doi: 10.1016/j.ejim.2022.08.015. Epub 2022 Aug 16.

Authors

Muhammad Ali Tariq¹, Hamza Amin², Qazi Shurjeel², Ahmed Gang³, Ashar Mohiuddin⁴

Affiliations

¹ Dow University Hospital, Dow International Medical College, Karachi, Pakistan. Electronic address: m.alitariqpk@gmail.com.
² Ruth KM Pfau Civil Hospital, Dow University of Health Sciences, Karachi, Pakistan.
³ Jinnah Postgraduate Medical Center, Karachi, Pakistan.
⁴ Dow University Hospital, Dow International Medical College, Karachi, Pakistan.

PMID: 35985949
DOI: 10.1016/j.ejim.2022.08.015

No abstract available

Publication types

Letter

MeSH terms

Diabetes Mellitus, Type 2* / drug therapy
Glucagon-Like Peptides / adverse effects
Humans
Hypoglycemic Agents / adverse effects
Obesity
Overweight* / complications

Substances

semaglutide
Glucagon-Like Peptides
Hypoglycemic Agents